aTYR PHARMA INC (ATYR): Nasdaq/NYSE listing notice — aTyr Pharma receives Nasdaq extension to Nov 30, 2026 to cure bid price deficiency

aTYR PHARMA INC

Original bid price deficiency notice received Dec 4, 2025; stock closed below $1.00 for 30 consecutive days.
On June 3, 2026, Nasdaq granted additional 180-day compliance period until November 30, 2026.
Company must maintain closing bid price >= $1.00 for 10 consecutive business days to regain compliance.
aTyr intends to cure deficiency via reverse stock split if necessary during second compliance period.
Failure to regain compliance by Nov 30, 2026 may result in delisting from Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

aTYR PHARMA INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

June 3, 2026, the Company received a letter from the Staff (the “Letter”) notifying the Company that the Company is eligible for an additional 180-day period, or until November 30, 2026 (the “Compliance Date”), to regain compliance, based on the Staff’s determination of the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compl

View on SEC.gov

Browse all listing & compliance notices →

aTYR PHARMA INC filing history →

Source: SEC EDGAR

accession 0001339970-26-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.